Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Cheryl Cohen Biography and Net Worth

Director of ImmunityBio

Cheryl L. Cohen is on the board of Aerpio Therapeutics, Inc. and 4 other companies.

In her past career Ms. Cohen held the position of President of CLC Consulting LLC, Vice President-Strategic Commercial Group at Health Care Systems, Inc., Vice President-Rheumatology Franchise at Centocor, Inc., Principal at Solvay Pharmaceuticals, Inc., Chief Commercial Officer of Medivation LLC (California) and Vice President for Janssen Biotech, Inc.

Cheryl L. Cohen received an undergraduate degree from Saint Joseph College.

What is Cheryl Cohen's net worth?: The estimated net worth of Cheryl Cohen is at least $1.06 million as of August 20th, 2021. Ms. Cohen owns 215,418 shares of ImmunityBio stock worth more than $1,057,702 as of April 18th. This net worth evaluation does not reflect any other investments that Ms. Cohen may own. Learn More about Cheryl Cohen's net worth.
How do I contact Cheryl Cohen?: The corporate mailing address for Ms. Cohen and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on Cheryl Cohen's contact information.
Has Cheryl Cohen been buying or selling shares of ImmunityBio?: Cheryl Cohen has not been actively trading shares of ImmunityBio during the last quarter. Most recently, Cheryl Cohen sold 14,801 shares of the business's stock in a transaction on Monday, August 23rd. The shares were sold at an average price of $10.12, for a transaction totalling $149,786.12. Following the completion of the sale, the director now directly owns 215,418 shares of the company's stock, valued at $2,180,030.16. Learn More on Cheryl Cohen's trading history.
Who are ImmunityBio's active insiders?: ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.
Are insiders buying or selling shares of ImmunityBio?: In the last year, ImmunityBio insiders bought shares 2 times. They purchased a total of 96,915 shares worth more than $268,516.25. The most recent insider tranaction occured on June, 5th when Director Michael D Blaszyk bought 71,915 shares worth more than $197,766.25. Insiders at ImmunityBio own 83.4% of the company. Learn More about insider trades at ImmunityBio.
Information on this page was last updated on 6/5/2023.

Cheryl Cohen Insider Trading History at ImmunityBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/23/2021	Sell	14,801	$10.12	$149,786.12	215,418
8/20/2021	Sell	9,976	$10.00	$99,760.00	215,418
8/17/2021	Sell	43,398	$10.12	$439,187.76

Cheryl Cohen Buying and Selling Activity at ImmunityBio

ImmunityBio Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Today's Range

Now: $4.91

$4.91

$5.28

50 Day Range

MA: $5.14

$3.50

$6.17

2 Week Range

Now: $4.91

$1.25

$6.93

Volume

3,512,544 shs

Average Volume

4,018,936 shs

Market Capitalization

$3.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad